Primary and secondary outcomes of the toolkit intervention.

a<p>Adjusting for age, sex, diabetes duration, previous cardiovascular disease, and practice diabetes patient volume.</p>b<p>Among patients aged ≥65 years who were not already receiving the medication at baseline.</p><p>ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; ICC, intraclass correlation coefficient; OR, odds ratio.</p

Flow chart of practice and patient randomization in the trial.

<p>Flow chart of practice and patient randomization in the trial.</p

Patient and practice baseline characteristics, by study group.

<p><b>Number (%) except where indicated.</b></p>a<p>Only available in the clinical data study.</p>b<p>Only available in the administrative data study. Measured in the 10 months prior to the start of follow-up.</p>c<p>Among patients aged ≥65 years: 211,137 in the intervention group, 208,286 in the control group.</p><p>ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; SD, standard deviation.</p